Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial.

Publikation

Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial.

Wissenschaftlicher Artikel/Review - 03.05.2021

Müllhaupt Gautier, Güsewell Sabine, Schmid Hans-Peter, Zumstein Valentin, Betschart Patrick, Engeler Daniel, Abt Dominik

Zitation

Müllhaupt G, Güsewell S, Schmid H, Zumstein V, Betschart P, Engeler D, Abt D. Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial. BMJ Open 2021; 11:e046973.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

BMJ Open 2021; 11

Veröffentlichungsdatum

03.05.2021

eISSN (Online)

2044-6055

Seiten

e046973

Kurzbeschreibung/Zielsetzung

A novel method for the surgical treatment of benign prostatic hyperplasia (BPH) called Aquablation has become commercially available. Previous studies have been able to show similar functional results when compared with transurethral resection of the prostate and a high efficacy has been demonstrated when this approach is applied to patients with a prostate size of 80-150 cm.Holmium laser enucleation of the prostate (HoLEP) is a well-established procedure in the surgical treatment of BPH in prostate glands larger than 30 mL and a first-line therapy in glands over 80 mL. To date, no data are available whether Aquablation is non-inferior compared with HoLEP in the treatment of patients with medium-to-large-sized prostates regarding safety and efficacy.